Table 2.

Treatment options for HAE attacks in the USA approved by the Food and Drug Administration (FDA) [12–21, 25–29]

Drug	Indication
Plasma-derived C1-INH (Berinert)	Acute abdominal, facial or laryngeal HAE attacks in adult and paediatric patients
Plasma-derived C1-INH (Cinryze)	Routine prophylaxis against angioedema attacks in adults, adolescents and paediatric patients (6 years of age and older) with HAE
Recombinant C1-INH (Ruconest)	Acute attacks of HAE in adult and adolescent patients with HAE
Icatibant, synthetic bradykinin B2 receptor antagonist (Firazyr)	Acute attacks of HAE in adults 18 years of age and older
Ecallantide, synthetic kallikrein inhibitor (Kalbitor)	Acute attacks of HAE in patients 12 years of age and older
FFP	Deficiency of coagulation factors or plasma protein, when alternative therapies are not available